Endocrine Reviews, doi:10.1210/er.2007-0010
Endocrine Reviews 28 (6): 653-663
Copyright © 2007 by The Endocrine Society
SNAREing Voltage-Gated K+ and ATP-Sensitive K+ Channels: Tuning ß-Cell Excitability with Syntaxin-1A and Other Exocytotic Proteins
Yuk M. Leung1,
Edwin P. Kwan1,
Betty Ng,
Youhou Kang and
Herbert Y. Gaisano
Department of Physiology (Y.M.L.) and Graduate Institute of Neural and Cognitive Sciences (Y.M.L.), China Medical University, Taichung 40402, Taiwan; and Departments of Medicine and Physiology (E.P.K., B.N., Y.K., H.Y.G.), University of Toronto, Toronto, Canada M5S 2A8
Correspondence: Address all correspondence and requests for reprints to: Dr. Herbert Gaisano, Room 7226, Medical Sciences Building, University of Toronto, Toronto, Ontario, Canada M5S 2A8. E-mail: herbert.gaisano{at}utoronto.ca; or Dr. Yuk-Man Leung, Department of Physiology, China Medical University, Taichung 40402, Taiwan. E-mail: ymleung{at}mail.cmu.edu.tw
 |
Abstract
|
|---|
The three SNARE (soluble N-ethylmaleimide-sensitive factor attachment protein receptor) proteins, syntaxin, SNAP25 (synaptosome-associated protein of 25 kDa), and synaptobrevin, constitute the minimal machinery for exocytosis in secretory cells such as neurons and neuroendocrine cells by forming a series of complexes prior to and during vesicle fusion. It was subsequently found that these SNARE proteins not only participate in vesicle fusion, but also tether with voltage-dependent Ca2+ channels to form an excitosome that precisely regulates calcium entry at the site of exocytosis. In pancreatic islet ß-cells, ATP-sensitive K+ (KATP) channel closure by high ATP concentration leads to membrane depolarization, voltage-dependent Ca2+ channel opening, and insulin secretion, whereas subsequent opening of voltage-gated K+ (Kv) channels repolarizes the cell to terminate exocytosis. We have obtained evidence that syntaxin-1A physically interacts with Kv2.1 (the predominant Kv in ß-cells) and the sulfonylurea receptor subunit of ß-cell KATP channel to modify their gating behaviors. A model has proposed that the conformational changes of syntaxin-1A during exocytosis induce distinct functional modulations of KATP and Kv2.1 channels in a manner that optimally regulates cell excitability and insulin secretion. Other proteins involved in exocytosis, such as Munc-13, tomosyn, rab3a-interacting molecule, and guanyl nucleotide exchange factor II, have also been implicated in direct or indirect regulation of ß-cell ion channel activities and excitability. This review discusses this interesting aspect that exocytotic proteins not only promote secretion per se, but also fine-tune ß-cell excitability via modulation of ion channel gating.
- I. Introduction
- II. Syn-1A Interaction with Kv Channels
- A. Syn-1A inhibits Kv currents and modulates Kv channel gating
- B. Syn-1A inhibition of Kv2.1 depends on the conformation of Syn-1A
- C. Reciprocal regulation of Kv2.1 and VDCC by closed/open forms of Syn-1A: implications
- D. Syn-1A affects Kv2.1 channel trafficking
- III. Syn-1A Interaction with KATP Channels
- A. WT Syn-1A inhibits KATP channels through SUR1 NBF1
- B. Open form Syn-1A inhibits KATP channels through NBF1 and NBF2
- C. Syn-1A modulates ß-cell KATP channel sensitivity to KATP channel openers
- IV. Regulation of ß-Cell Functions by RIM and GEFII
- A. Rab3A-interacting molecule (RIM) and guanyl nucleotide exchange factor (GEF)
- B. Do RIM/GEFII regulate ß-cell ion channels?
- V. Regulation of Syn-1A Conformational Changes by Munc13 and Tomosyn
- VI. Conclusion and Future Perspectives
 |
I. Introduction
|
|---|
IN SECRETORY CELLS such as neurons and neuroendocrine cells, Ca2+ influx triggers secretory vesicle exocytosis, releasing neurotransmitters or hormones. A prerequisite for vesicle exocytosis is the interaction of a SNARE (soluble N-ethylmaleimide-sensitive factor attachment protein receptor) protein on the vesicle membrane with its cognate SNAREs on the plasma membrane, a process in preparation for lipid reorientation that proceeds to membrane fusion (1, 2, 3, 4, 5). Much insight has been gained in examining the role of SNARE proteins in neurotransmitter release (1, 2, 3, 4, 5), and subsequently, also in insulin exocytosis in pancreatic islet ß-cells (6, 7, 8). SNARE proteins share the common characteristic of a central coiled-coil SNARE motif, which is a 60–70 amino-acid cytosolic domain essential for SNARE-SNARE recognition and interaction (1, 2, 3, 4, 5). Assembly of vesicle SNARE protein synaptobrevin with the plasma membrane target-SNARE proteins SNAP-25 and syntaxin-1A (Syn-1A) forms the "trans"-SNARE complex, which juxtaposes the vesicular membrane to the plasma membrane (1, 2, 3, 4, 5). During membrane fusion triggered by Ca2+, the SNARE complex adopts the "cis"-configuration.
A process termed "priming" precedes the formation of the trans-SNARE complex. Before priming, Syn-1A exists in the closed conformation whereby its N-terminal HABC domain folds back onto its C-terminal H3 domain (2, 9, 10, 11, 12). This blocks the active sites (SNARE motif) within H3 domain from interacting with SNARE motifs within SNAP-25 and synaptobrevin to form the SNARE complex. Activation of Syn-1A from the closed conformation to the open form is therefore a key event required to enable SNARE complex assembly (therefore, priming), and Munc13 and Munc18 have been implicated in the Syn-1A conformation changes (see Refs. 2 and 9, 10, 11, 12 ; also see Section V).
In islet ß-cells, opening of voltage-dependent Ca2+ channels (VDCCs) provides the Ca2+ influx required to trigger exocytotic fusion of insulin granules (13). VDCC is a complex of several subunits, namely
1,
2,
, ß, and in some VDCC members a
-subunit (for a review, see Ref. 14). The
1-subunit forms the ion-conducting channel pore, whereas other subunits may serve to enhance channel expression and/or modify channel gating. The
1-subunit is a single polypeptide consisting of four homologous repeats (I–IV) clustering around the center pore, with each repeat having six transmembrane helices (S1–S6). S4 is the voltage sensor for channel activation, whereas the P-loop is between S5 and S6; the P-loops from the four repeats are believed to constitute the Ca2+ ion selectivity filter (14).
SNARE proteins were subsequently shown to be tethered to the cytoplasmic domain between the second and third repeats of various VDCCs, including VDCCs found in islet ß-cells (15, 16, 17, 18). There are two obvious strategic advantages of such a molecular arrangement. First, it ensures rapid release response because the secretory machinery (SNARE complex) is immediately exposed to a high local Ca2+ concentration permeating through the VDCCs to trigger membrane fusion (15, 16, 17). Second, the SNARE proteins can, depending on the status of the exocytotic cycle, provide feedback to the VDCC to control the rate and amount of Ca2+ influx (15, 16, 17, 19, 20, 21, 22). Such an intimate physical and functional coupling among the secretory vesicle-SNARE protein-Ca2+ channel complex has been termed excitosome in ß-cells (16) and neurons (19).
VDCC gating is finely regulated by changes in membrane potential. In pancreatic ß-cells, membrane potential is modulated mainly by ATP-sensitive K+ (KATP) and voltage-gated K+ (Kv) channels (13, 23, 24). When pancreatic islet ß-cells are exposed to high glucose, the raised ATP/ADP ratio in the cytosol causes closure of KATP channels. Cessation of K+ efflux due to shutting down of KATP channels, together with a continuous depolarizing current of yet unidentified nature, results in ß-cell membrane depolarization. The latter activates VDCC, leading to Ca2+ influx and ensuing exocytosis (13, 23). As a result of ß-cell membrane depolarization, Kv channels also become activated, providing K+ efflux necessary to repolarize the cell membrane. Subsequently, repolarization closes VDCC, leading to cessation of Ca2+ influx and termination of exocytosis (24).
It would be of interest to ask whether and how these K+ channels (Kv, KATP) in the ß-cell could be intimately coupled to the exocytotic cycle. Toward this, substantial insights have been obtained over the last several years that demonstrated that SNARE proteins, mainly Syn-1A, physically and functionally interact with ß-cell Kv2.1 (the predominant Kv in ß-cells) and KATP channels (25, 26, 27, 28, 29, 30, 31). These reports support the notion that SNARE proteins do not only participate in exocytosis per se, but also regulate excitability by modulating the ion channels involved in secretion. It is of particular importance to note that SNARE protein levels are severely reduced in islets of diabetic rodents and humans (32, 33, 34, 35), which would be expected to contribute to the dysregulation of these ß-cell secretory steps in diabetes. Remarkably, restoration of these deficient SNARE proteins in islets of type 2 diabetic rodent models could normalize insulin secretion (32, 36), which has therapeutic implications.
In this review, we explain how Syn-1A modulates the gating of Kv2.1, VDCC, and KATP channels to fine-tune ß-cell excitability. Munc-13, tomosyn, rab3a-interacting molecule (RIM) and guanyl nucleotide exchange factor II (GEFII) are also known to modulate vesicle fusion per se, but they could also be involved in direct or indirect regulation of ß-cell ion channel activities and excitability, which we also discuss in this review.
 |
II. Syn-1A Interaction with Kv Channels
|
|---|
A. Syn-1A inhibits Kv currents and modulates Kv channel gating
A Kv channel is composed of
- and ß-subunits. Although the
-subunit is the conducting pore, the ß-subunit is a modifier of channel gating (37). The Kv
-subunit comprises four polypeptides clustering around a central pore. The T1 region is the domain in the N terminus responsible for tetramerization of the polypeptides (37). Each polypeptide subunit has six transmembrane helices (S1–S6). Similar to VDCC, S4 is the voltage sensor, whereas the P-loop is between S5 and S6; the P-loops from the four polypeptide subunits form the K+ selectivity filter (38). In all K+ channels, there is a well-conserved "sequence signature," TVGYG, which lines the selectivity filter (38).
Kv1.1, a Kv channel abundant in neurons, was the first Kv channel shown to interact with Syn-1A (25). Physical interaction between Kv1.1 and Syn-1A was shown in rat brain synaptosomes using reciprocal coimmunoprecipitation. Kv1.1 gating (existing as Kv1.1/Kvß channel complex) was shown to be modulated by Syn-1A, which caused an increase in the extent of inactivation, possibly by binding to the ß-subunit and increasing its efficacy in causing inactivation. Syn-1A decreases Kv1.1 current magnitude by binding to the N terminus of Kv1.1 (26). The expression of Kv1.1 is, however, very low in insulinoma HIT-T15 cells and undetectable in rat islet ß-cells, arguing against an involvement of Kv1.1 in ß-cell excitability regulation (39). It was further found that Syn-1A and SNAP-25 modulated Kv channels in cardiac myocytes (40) and esophageal smooth muscles (41), respectively. These reports establish a new paradigm that SNARE proteins can directly modulate the Kv channel superfamily.
In pancreatic islet ß-cells, Kv2.1 is the major (70%) delayed rectifier K+ channel (39, 42). Syn-1A and SNAP25 colocalized with both Kv2.1 and Cav1.2 (L-type VDCC) in lipid raft microdomains within HIT-T15 ß-cell plasma membranes, and these lipid raft domains contain other components of the SNARE exocytotic machinery (43). This raised the possibility that SNARE proteins could be forming additional excitosomes with Kv channels (43). In support, coimmunoprecipitation experiments on a heterologous expression system demonstrated a molecular complex consisting of Syn-1A, SNAP25, and Kv2.1 (44). In fact, in neuroendocrine PC12 cell line, it was just reported that direct association of Syn-1A to Kv2.1 promoted exocytosis (45). It would be of interest to examine whether such a Kv2.1-containing excitosome also occurs in islet ß-cells. It has been reported that SNAP-25 binds to the N terminus of Kv2.1 to inhibit current amplitude (44). This role of SNAP-25 on Kv2.1 was confirmed in ß-cells whereby SNAP-25 was cleaved by botulinum neurotoxins (46).
When the structure-functional interaction of Kv2.1 with Syn-1A was examined, Syn-1A was shown to bind strongly to the cytoplasmic C-terminal fragments (C1, amino acids 412–633; C2, amino acids 634–853), and only weakly to the cytoplasmic N terminus (amino acids 1–182), of Kv2.1 (27). Dialysis of recombinant Syn-1A into ß-cells or HEK cells expressing Kv2.1 caused inhibition of currents, which could be prevented by codialysis of C1 or C2 fragments, but not N-terminus protein (27). This would suggest that Syn-1A inhibition of Kv2.1 is mediated through the C terminus, which is in contrast to Kv1.1, where Syn-1A inhibition is mediated via the channel N terminus (26). This demonstrates that SNARE proteins interact with distinct domains within the different Kv members, which is in stark contrast to the VDCC superfamily, where SNARE proteins interact with a common conserved cytoplasmic domain linking transmembrane repeats II and III, termed the synprint site, which is present in all high voltage-activated VDCC members (15, 16, 17).
Syn-1A not only reduces Kv2.1 current amplitude, but also changes its gating behavior (27). Coexpressing Syn-1A with Kv2.1 in HEK cells increases the voltage sensitivity of steady-state inactivation of Kv2.1 over a range of physiologically relevant membrane potential (–40 to 0 mV), suggesting that Syn-1A decreases channel availability upon steady-state depolarization. Furthermore, in the presence of Syn-1A, Kv2.1 channel activation becomes slower (27). This is, however, not accompanied by a significant change in voltage-dependence of activation.
Pharmacological blockade of Kv2.1 can effectively potentiate glucose-stimulated insulin secretion in ß-cells, suggesting that Kv2.1 is a potential drug target in the treatment of diabetes (24, 47). Insights into SNARE-Kv2.1 interaction may therefore reveal potential novel strategies to optimize insulin secretion.
B. Syn-1A inhibition of Kv2.1 depends on the conformation of Syn-1A
More recently, efforts have been made to examine whether the conformational changes of Syn-1A from closed form to open form occurring during exocytosis would have distinct actions on Kv2.1 gating (31), perhaps in a manner that would dynamically modulate the rate of membrane repolarization conducive to optimizing exocytosis. To examine the specific actions of the activated open form Syn-1A, the mutant Syn-1A, which is constitutively open by the introduction of two mutations at the linker region (L165A, E166A) (9, 12), was employed. A note of caution is that in previous reports showing Syn-1A regulation of Kv channels and VDCC, the form of Syn-1A used was the wild type (WT) (20, 25, 26, 27, 28). A study using single-molecule fluorescence resonance energy transfer measurement demonstrated that Syn-1A in solution exhibits a rapid dynamic equilibrium between the closed and open forms (48). Dialysis of recombinant proteins of open form or WT Syn-1A into Kv2.1-expressing HEK cells showed that open form Syn-1A is more potent than WT Syn-1A in inhibiting Kv2.1 currents (31). The structural determinant of Syn-1A was identified to be the C-terminal H3 domain, which putatively mediates Kv2.1 inhibition (31).
Overexpression of WT or open form Syn-1A in HEK cells expressing Kv2.1 showed that open form Syn-1A slows down Kv2.1 activation much more than WT Syn-1A (31). Open form Syn-1A also reduced Kv2.1 channel availability to a larger extent than WT Syn-1A upon steady-state depolarization (31). Because WT Syn-1A "flip-flops" between the closed and open forms (48), it is reasonable to speculate that closed form Syn-1A inhibits Kv2.1 less than WT Syn-1A. Unfortunately, there is so far no constitutively closed form Syn-1A reported to verify this point.
C. Reciprocal regulation of Kv2.1 and VDCC by closed/open forms of Syn-1A: implications
L-type VDCC has been accepted to be the predominant VDCC involved in both the first and second phase of glucose-stimulated insulin secretion in human, rat, and mouse islets and insulin-secreting ß-cell lines (16, 49, 50). It mediates Ca2+ entry required for triggering insulin exocytosis in KATP channel-dependent first phase insulin secretion. It also regulates intracellular Ca2+ signaling to replenish releasable insulin granules during KATP channel-independent second phase insulin secretion. Interaction of VDCC with SNARE proteins has been well documented (19). Specifically, Syn-1A has been shown to modulate L-type VDCC activities in pancreatic ß-cells and ß-cell lines (18, 20).
In a species-specific fashion, N-type VDCC has also been implicated in ß-cell secretion (50). For example, N-type VDCC has been found in INS-1 rat insulinoma cells and rat ß-cells; and inhibition of N-type VDCC with
-conotoxin blocks glucose-stimulated insulin release (51, 52, 53, 54, 55). N-type VDCC inhibition by
-conotoxin also blocks human ß-cell hormonal secretion (52). Zamponis group (22) has shown that WT and open forms of Syn-1A have differential effects on N-type VDCC gating. Thus, it was demonstrated that whereas both WT and open form Syn-1A equally support G protein inhibition of N-type VDCC, the availability of N-type VDCC was only decreased by WT Syn-1A, but not by open form Syn-1A. This is in contrast to the stronger inhibition of Kv2.1 by open form Syn-1A than WT Syn-1A (31).
What is the biological implication of the above-described reciprocal modulation of VDCC and Kv channels by Syn-1A conformational changes? We hypothesize that such reciprocal modulation optimally regulates cell excitability and thus exocytosis (Fig. 1
). When insulin granules are docked onto the plasma membrane and the ß-cell is at resting state, Syn-1A assumes the closed form (Fig. 1A
). Closed form Syn-1A reduces VDCC (N-type or L-type) availability and has minimal inhibition on Kv2.1. The process of priming in exocytosis leads to a conformational change of Syn-1A to its open form, which exerts a stronger inhibition on Kv2.1 but loses its effect on VDCC availability (Fig. 1B
). At this primed state, both Kv2.1 channel and VDCC are still shut, rendering inhibition by any form of Syn-1A immaterial. Depolarization of the ß-cell opens both Kv2.1 and VDCC (Fig. 1C
). Because the open form of Syn-1A does not decrease VDCC availability (22), it allows maximal Ca2+ influx. The open form of Syn-1A strongly inhibits Kv2.1 to limit K+ efflux, thus slowing down repolarization and consequently augmenting Ca2+ influx during exocytosis. The SNARE core complex disassembles after exocytosis, and Syn-1A resumes its closed form (Fig. 1D
). VDCC availability now becomes much reduced because of interaction with closed form Syn-1A. Ca2+ influx is then substantially attenuated. Meanwhile, the closed form Syn-1A inhibits Kv2.1 only weakly, permitting more K+ efflux and thus speeding up repolarization. Eventually, both the VDCC and Kv2.1 channels close, because the ß-cell repolarizes to its resting membrane potential (Fig. 1A
).

View larger version (61K):
[in this window]
[in a new window]
|
FIG. 1. Gating of Kv2.1 and N-type VDCC are differentially modulated by conformational changes of Syn-1A. A, Cell is at resting potential with channels closed. Closed form Syn-1A mildly inhibits Kv2.1 but strongly inhibits N-type VDCC. B, Syn-1A is in open form after priming. C, Depolarization opens Kv2.1 and N-type VDCC. Open form Syn-1A strongly inhibits Kv2.1 without significant effect on N-type VDCC. D, Upon disassembly of core complex, Syn-1A resumes its closed form, whose strong inhibition of N-type VDCC limits Ca2+ influx. Meanwhile, mild inhibition of Kv2.1 by closed form Syn-1A permits more K+ efflux and thus speeds up repolarization (for detailed explanation see text).
|
|
D. Syn-1A affects Kv2.1 channel trafficking
When Kv2.1 is coexpressed with Syn-1A in HEK cells, data from confocal microscopy and biotinylation experiments show that Syn-1A inhibits the trafficking of Kv2.1 to the cell surface (27). In a subsequent work, WT Syn-1A and open form Syn-1A were shown to be equally effective in inhibiting Kv2.1 surfacing, although open form Syn-1A is more potent than WT Syn-1A in inhibiting Kv2.1 current amplitude and gating (31). Although these works suggest that overexpression of Syn-1A could inhibit Kv2.1 trafficking, the endogenous and presumably lower expression of Syn-1A may actually have the role of promoting Kv2.1 surfacing. Thus, it has recently been shown that cleavage of Syn-1A and SNAP-25 by botulinum toxins blocks the trafficking of Kv2.1 to the plasma membrane in cortical neurons (56). It would be of interest to examine whether botulinum toxin C cleavage of Syn-1A would affect Kv2.1 trafficking in ß-cells.
 |
III. Syn-1A Interaction with KATP Channels
|
|---|
A. WT Syn-1A inhibits KATP channels through SUR1 NBF1
KATP channels play an important role in coupling cell metabolism and membrane excitation in ß-cells (13, 23). In low glucose, low ATP concentration in ß-cells allows KATP channels to open partially, thus keeping ß-cells from depolarizing. In high glucose, the raised ATP/ADP ratio closes KATP channels, leading to membrane depolarization, which opens VDCC to allow Ca2+ influx to evoke exocytosis.
A KATP channel has two dissimilar components, namely, Kir6 [a member of inward rectifier K+ (Kir) channels] and sulfonylurea receptor (SUR). Functionally mature KATP channels in ß-cells are heterooctamers, composed of four Kir6.2 subunits and four SUR1 subunits (57, 58). The Kir6 subunit is the ion-conducting pore, whereas SUR is the subunit regulating channel gating (for reviews, see Refs. 59, 60, 61). ATP inhibits the KATP channel by directly binding to Kir6. SUR comprises of an N-terminal TMD0 domain, and the TMD1 and TMD2 domains. For TMD1 and TMD2, each has six transmembrane helices; and there are two cytoplasmic nucleotide-binding folds (NBFs), namely, NBF1 (between TMD1 and TMD2) and NBF2 (at TMD2 C terminus). Convincing evidence has suggested that NBFs are sites for regulation by adenine nucleotides (e.g., MgADP activation), sulfonylurea drugs (e.g., inhibition by glibenclamide), KATP channel openers (such as activation by diazoxide) (57, 59, 60, 61), and Syn-1A (see below).
Considerable insights into the structure-function of KATP channels (SUR1/Kir6.2) in controlling ß-cell insulin secretion have arisen from reports of genetic mutations causing either loss-of-function (defective KATP channel opening) or gain-of-function (persistent KATP channel opening) of the channel, which, respectively, result in congenital hyperinsulinemia or neonatal diabetes mellitus (reviewed in Ref. 61).
It could be pondered whether auxiliary proteins may modulate KATP channel gating. Because Syn-1A has been shown to affect Kv channels and VDCC, whether Syn-1A could also affect ß-cell KATP channel functions to even more exquisitely modulate membrane excitability during exocytosis was subsequently examined. Thus, it has been shown in insulinoma HIT-T15 cells and rat ß-cells that dialysis of recombinant Syn-1A inhibited KATP channel opening in the presence of low cytosolic ATP concentration (29), indicating that Syn-1A could further enhance ß-cell excitability by closing KATP channels. In concordance, cleavage of endogenous Syn-1A by expressing botulinum neurotoxin C1 in HIT-T15 cells increased KATP currents, indicating that endogenous Syn-1A exerts a constitutive suppressive action on endogenous KATP channels (29).
Inhibition of KATP channels by Syn-1A is of importance because Syn-1A levels are severely reduced in islets of diabetic rodents and humans (32, 33, 34, 35). Islet ß-cell KATP channel activities of these diabetic rodents and humans may therefore be less inhibited, contributing to the reduced glucose-stimulated insulin secretion (32, 33, 34, 35). Insulin secretion in type 2 diabetic patients is characterized by elevated basal release, abrogated glucose-stimulated first phase release, and reduced glucose responsiveness of second phase release (62). Despite much work, the precise mechanisms underlying this discrepant insulin secretory response remain undefined. This could be due to dissimilar exocytotic pathways for basal (constitutive) and glucose-stimulated release, with Syn-1A playing no role or only a very minor role in basal release. Strong evidence for this notion comes from a recent study showing that basal insulin release is unaffected in Syn-1A knockout mice, which nevertheless have severely impaired first- and second-phase insulin secretion (63).
Syn-1A binds SUR1 at its NBF1 and NBF2 with equal affinity (29). However, codialysis of NBF1, but not NBF2, blocked Syn-1A inhibition, suggesting that Syn-1A inhibition of KATP channels is transduced via NBF1. Syn-1A does not bind the N terminus of SUR1 (Y. Kang and H. Y. Gaisano, unpublished results), nor does it bind the Kir6.2 subunit (29). Because overexpression of Syn-1A affects Kv2.1 trafficking to the plasma membrane in HEK 293 cells (27), it is possible that Syn-1A may also affect the trafficking of KATP channels, which remains to be examined.
B. Open form Syn-1A inhibits KATP channels through NBF1 and NBF2
More recently, whether the conformation status of Syn-1A affects its ability to inhibit ß-cell KATP channels was investigated (30). Open form Syn-1A inhibits KATP channels with similar efficacy as WT-Syn-1A; the H3 domain, not the HABC domain, is responsible for the inhibitory action. Interestingly, open form Syn-1A and H3 domain differ from WT-Syn-1A in their mode of inhibition (30). Codialysis of NBF1 or NBF2 is equally effective in blocking open form Syn-1A (or H3) inhibition of KATP channels, indicating that open form Syn-1A transduces its inhibition of KATP channels via both NBF1 and NBF2, in contrast to WT Syn-1A, which seems to act mainly on NBF1. Therefore, the way Syn-1A interacts with SUR1 also depends on Syn-1A conformation, which led us to propose a model in Fig. 2
. Because ADP is known to interact with NBF2 (but not NBF1) to activate ß-cell KATP channel (64), inhibition of KATP channels by open form Syn-1A via binding to NBF2 might interfere with ADP action.

View larger version (44K):
[in this window]
[in a new window]
|
FIG. 2. Conformational status of Syn-1A affects the manner in which it interacts with the SUR1 subunit of the KATP channel. A, Cell is at resting state with KATP channels mediating outward K+ currents. Closed form Syn-1A inhibits KATP channel opening through interaction with NBF1. MgADP stimulates KATP channel opening through interaction with NBF2. B, After priming, Syn-1A opens up; the H3 domain inhibits KATP channel opening through interaction with both NBF1 and NBF2. This potentially counteracts the stimulatory effect of MgADP on NBF2.
|
|
C. Syn-1A modulates ß-cell KATP channel sensitivity to KATP channel openers
By hyperpolarizing ß-cell membrane potential, SUR1-selective KATP channel openers induce "ß-cell rest" and have been developed as a novel therapeutic approach to counter the effects of ß-cell overstimulation in diabetes (65, 66, 67, 68, 69). The potential therapeutic implication of Syn-1A-SUR1 interaction was most recently demonstrated by studying the effects of Syn-1A on the actions of a potent ß-cell-selective KATP channel opener, NNC 55–0462 (70). In this study, WT Syn-1A was found to decrease the potency and efficacy of NNC 55-0462 and its parent compound diazoxide in activating KATP channel in rat islet ß-cells. These inhibitory effects of Syn-1A on NNC 55-0462 drug action could be mimicked by the Syn-1A H3 domain (70). In agreement with our results, in Zucker obese diabetic rats whose islets have severely reduced Syn-1A levels (34), SUR1-selective KATP channel opener NN414 is more effective in attenuating hyperinsulinemia than in their lean controls (71). Thus, the severely reduced islet Syn-1A levels found in diabetes may indeed enhance the therapeutic efficacy of SUR1-selective KATP channel openers to induce ß-cell rest.
 |
IV. Regulation of ß-Cell Functions by RIM and GEFII
|
|---|
A. Rab3A-interacting molecule (RIM) and guanyl nucleotide exchange factor (GEF)
Glucagon-like peptide-1 (GLP-1), a potential antidiabetogenic agent, is capable of bypassing the secretory defects of the diabetic islets to correct the insulin secretory response (72, 73). These defects include a reduction in islet levels of SNARE proteins (32, 33, 34). GLP-1 also inhibited Kv2.1 in ß-cells to attenuate membrane repolarization (74, 75). These GLP-1 effects on Kv2.1 are mediated by dual activation of cAMP/protein kinase A (PKA) and epidermal growth factor receptors [and subsequent phosphoinositol-3 kinase and protein kinase C
signaling] (75). The precise molecular substrates for the cAMP/PKA pathways are, however, unclear but may involve RIM and GEFII.
RIM proteins have a critical role in vesicle priming. RIM1-knockout mice exhibited a reduction in the probability of neurotransmitter release (76, 77). However, RIM2 (1590 amino acids), which possesses 62% identity to RIM1, is more abundant than RIM1 in islet ß-cells (78, 79). RIM2 contains all of the functional domains of RIM1 and exhibits similar interactions with RIM1-binding proteins, which are also present in islet ß-cells (78, 79, 80). PKA phosphorylates RIM1 at Ser413 (between zinc finger and PDZ domain) and Ser1548 at the very C terminus (Fig. 3
) (81). The very N terminus of RIM1 binds Rab3a, which serves to tether the vesicle to the plasma membrane (82, 83, 84). An adjacent domain (zinc finger domain) binds Munc13-1 to create a link between synaptic vesicle tethering and priming (85, 86) (Fig. 3
). A central PDZ domain binds GEFII, a presynaptic substrate directly activated by cAMP (78) (Fig. 3
).

View larger version (59K):
[in this window]
[in a new window]
|
FIG. 3. Interaction between Munc13, RIM, and GEFII and potential modulation of VDCC and KATP channels, respectively, by RIM and GEFII. RIM is under dual control by PKA (two phosphorylation sites) and GEFII (protein-protein interaction). GEFII is directly activated by cAMP. RIM also interacts with Munc13, which serves multiple roles in exocytosis including the opening up of Syn-1A. GEFII binds to SUR1 NBF1 of the KATP channel to regulate channel activities. The C terminus of RIM binds loosely to VDCC, and whether such binding regulates VDCC activities is hitherto unknown. For full explanation, see text.
|
|
The roles of RIM2 and GEFII in insulin secretion have been actively explored. Antisense treatment to reduce RIM2 or GEFII expression, or expression of their dominant-negative constructs, inhibited GLP-1 (and cAMP/PKA)-stimulated insulin secretion (78, 79, 80, 87, 88). RIM2 binds islet ß-cell rab3a (87) and Munc13-1 (a major diacylglycerol receptor) (89) to prime insulin exocytosis. Taken together, RIMs act as scaffolding proteins that serve as platforms for RIM-binding proteins to effect their actions or to form complexes with other proteins (Fig. 3
). Thus, GLP-1-activated cAMP/PKA signaling effects on ß-cell targets, including VDCC, Kv2.1, and KATP channels, may in part be mediated by independent or sequential actions on RIM2 and GEFII, which could potentially bypass the defective SNARE exocytotic machinery in diabetes mellitus.
B. Do RIM/GEFII regulate ß-cell ion channels?
RIM1-C2A and RIM1-C2B bind to
1B (pore-forming subunit of N-type VDCC) and
1C (pore-forming subunit of L-type VDCC) (90). In support, in giant calyx-type synapse of chick ciliary ganglion, it is shown by immunostaining that RIM and N-type VDCC (Cav2.2) strongly covary in expression at the presynaptic transmitter release site, suggesting that they are closely associated (91). However, in immunoprecipitation experiments, Cav2.2 does not coprecipitate with RIM or its binding partner Munc-13 (91). These suggest that Cav2.2 and RIM do not form a stable molecular complex. Whether RIM affects Ca2+ channel current amplitude or gating is hitherto unknown.
cAMP-GEFII has also been implicated as a signaling pathway downstream of Ca2+ influx (92). In rat insulin-secreting INS-1 cells, Cav1.2-mediated glucose-stimulated insulin secretion was activated by both GEFII-selective agonist 8-pCPT-2'-O-Me-cAMP and PKA-selective agonist N6-benzoyl-cAMP (their effects are additive), indicating involvement of both signaling pathways (92). In contrast, Cav1.3-mediated glucose-stimulated insulin secretion was only activated upon PKA activation, with GEFII activation only providing a potentiating role (92). However, there is no evidence showing direct binding of GEFII to VDCC, nor are there data indicating modulation of VDCC gating by cAMP-GEFII.
GEFII has been reported to directly bind to the NBF1 of SUR1, but not SUR1-NBF2 or SUR2A-NBF2 (80, 93). Recently, KATP channel activities in human ß-cells and rat INS-1 insulin-secreting cells have been shown to be inhibited by cAMP and GEFII-selective agonist 8-pCPT-2'-O-Me-cAMP, but not by 2'-O-Me-cGMP (cGMP analog) or PKA-selective agonist N6-benzoyl-cAMP (93). These data suggest direct modulation of the ß-cell KATP channel by cAMP-GEFII but not PKA-mediated phosphorylation. Intriguingly, it was shown that GEFII dissociates from SUR1 upon an elevation of cAMP concentration (80). This finding may indicate that GEFII on its own has a constitutively activating effect on the ß-cell KATP channel. The extent to which cAMP-GEFII-mediated inhibition of KATP channel activities affects insulin secretion remains to be investigated, but such inhibition presumably causes ß-cell membrane depolarization, promotes Ca2+ entry, and triggers exocytosis (93). Given our finding that Syn-1A also binds to NBF1 of SUR1 (29, 30), it would be interesting to dissect the interrelation of NBF1-Syn-1A-GEFII binding.
We have also tested whether RIM2/GEFII have any effect on Kv2.1. However, in HEK 293 cells expressing Kv2.1, coexpression of RIM2 and/or GEFII did not cause a significant effect on Kv2.1 channel current amplitude or gating (either in the absence or presence of 100 µM intracellular cAMP) (Y. M. Leung and H. Y. Gaisano, unpublished observations).
 |
V. Regulation of Syn-1A Conformational Changes by Munc13 and Tomosyn
|
|---|
Munc13-1 and its orthologs (Unc13 and Dunc13 in Caenorhabditis elegans and Drosophila, respectively) have been recently suggested as priming proteins by virtue of their hypothesized ability in displacing Syn-1A from Munc18-1, which would induce Syn-1A to switch from the closed to open form, which is then capable of interacting with its cognate SNARE partners to form a stable complex (9, 11, 12). The family of Munc13 isoforms belongs to the superfamily of C2 domain proteins (94, 95). Studies showed that overexpression of Munc13-1 increases the size of the readily releasable pool (RRP) of granules (96, 97), whereas neurons deficient of Munc13 or its orthologs exhibit a profound impairment in neurotransmitter release due to a near absence of RRP of synaptic vesicles (98, 99, 100). These results suggest a role for Munc13-1 in priming secretory vesicles for fusion. In fact, recent evidence reveals that Munc13-1-deficient mice exhibited severely reduced first and second phase insulin secretion accounted for by reduced RRP size and mobilization of insulin granules, leading to an abnormal glucose tolerance (101, 102). Remarkably, the level of Munc13-1 has been reported to be dramatically reduced in islets from type II diabetes models (33).
Of note, the priming action of Munc13-1 is hypothesized to be based on three observations. First, Munc13-1/Unc13 interacts with the HABC domain of Syn-1A (103, 104), presumably preventing the domain from folding back onto its H3 SNARE motif (9). Second, overexpression of open form Syn-1A restores fusion of synaptic vesicles in C. elegans Unc13-deletion mutants (12). Third, the interaction between Munc13-1/Unc13 and Syn-1A is essential for Munc13-1/Unc13 priming activity (104, 105). In light of reports from our group and others that Syn-1A regulates activities and/or availabilities of Kv2.1, KATP, and N-type VDCC in a conformation-dependent manner, it is tempting to hypothesize that the specific Syn-1A forms required for affecting the ion channels are actively regulated by the priming activity of Munc13-1.
It is noteworthy that there is no evidence so far that Munc13-1 directly interacts with any ion channel (at least with regard to exocytosis triggered by Ca2+ alone), based on several observations. First, Kv channel and VDCC activities are normal in pancreatic ß-cells from heterozygous Munc13-1 knockout mice (101). Second, maximal Ca2+ rise induced by ionomycin or photolysis of caged Ca2+ was unable to normalize fusion of synaptic vesicles and insulin granules (99, 102). Furthermore, Ca2+-dependent fusion and granule replenishment are unaltered in Munc13-1 deletion mutants (105).
Nonetheless, it should be remembered that the results mentioned above were obtained from protocols where Ca2+ was used as the sole trigger for exocytosis. Second messengers such as cAMP have been known to act synergistically with Ca2+ to potentiate release of neurotransmitters and exocytosis of granules (106). Similarly, GLP-1, and its mimetics being promising antidiabetogenic agents, have been well known to act via the cAMP signaling pathway to potentiate insulin exocytosis by severalfold, resulting in a partial bypass of insulin secretory deficiency in type II diabetes models (107). Remarkably, the potentiation is underscored by a marked increase in the size of RRP and replenishment of insulin granules and has been thought to be in part explained by alteration of ion channel activities in the ß-cells, such as those of Kv2.1 (74), L-type VDCC (108), and KATP channels (93). Alteration of activities of these channels is collectively associated with lower threshold for action potential and prolonged Ca2+ influx, hence suggestive of greater magnitude of insulin exocytosis.
Activation of PKA by cAMP has been shown to cause PKA-catalyzed phosphorylation of RIM, which interacts with the N-terminal domain of Munc13-1 via its Zn2+ finger region and modulates Munc13-1s priming activity (85, 86). Importantly, PKA-catalyzed phosphorylation of RIM has recently been implicated to profoundly increase recruitment of Munc13-1/Unc13 to exocytotic sites (109, 110). These observations suggest that cAMP/GLP-1 stimulation may lead to a dominant presence of open form Syn-1A in exocytotic sites.
Recent studies have suggested that besides Munc13-1, Syn-1A conformation may be affected by another protein called tomosyn. Tomosyn binds to the H3 SNARE motif of Syn-1A via its C-terminal VAMP homology region to form an inhibitory SNARE complex with Syn-1A and SNAP-25, reducing the availability of open form Syn-1A for assembly of functional SNARE complex (111, 112). Indeed, several studies have suggested that tomosyn negatively regulates catecholamine exocytosis of PC12 cells (111), adrenal chromaffin cells (113), and insulin exocytosis (114). Moreover, tomosyn-deletion C. elegans mutants have enhanced synaptic fusion of neurotransmitters due to increased number of RRP of primed vesicles (112). Remarkably, like the expression of open form Syn-1A, deletion of tomosyn nearly restores fusion of synaptic vesicles in Unc13 null nematodes (112). These results suggest that tomosyn acts antagonistically to Unc13/Munc13 to regulate fusion competence of secretory granules. Tomosyn may therefore be important in the indirect regulation of ß-cell ion channels by modulating Syn-1A conformations.
Interestingly, it has been reported that tomosyn is directly phosphorylated by PKA, resulting in decreased interaction with Syn-1A, increased formation of the functional SNARE complex, and increased size of RRP of primed synaptic vesicles (115). These observations thus shed light on an additional mechanism for the cAMP/GLP-1 pathway to alter ion channel activities in the ß-cells.
Of note, it was recently reported that reduction of tomosyn by RNA interference leads to impaired insulin exocytosis in a ß-cell line, INS-1E, suggesting that tomosyn positively regulates insulin secretion (116). However, it is not known in the study whether deficient tomosyn might indirectly cause reduced insulin secretion through perturbation of other exocytotic proteins that have direct positive roles in insulin secretion. This is in part supported by evidence in the study that overexpression of tomosyn did not potentiate insulin secretion, suggesting that the expression/function of tomosyn is not limiting (116). Therefore, the temporal patterns and possible cell-specific regulation of recruitment of Munc13-1 by RIM, alteration in tomosyn-Syn-1A interaction, and the resulting balance between closed and open form Syn-1A warrant further investigation.
 |
VI. Conclusion and Future Perspectives
|
|---|
Earlier works on Syn-1A-Ca2+ channel interaction, taken together with our works examining how Syn-1A inhibits Kv2.1 and KATP channels, strongly suggest that Syn-1A changes its conformation not only to prepare for and promote vesicle exocytotic fusion, but also to modulate the gating of these ion channels in a manner that optimally regulates membrane excitability. Thus, during priming for exocytosis in ß-cells, open form Syn-1A promotes KATP channel closing and the ensuing membrane depolarization. Once ß-cells are depolarized, open form Syn-1A may prolong depolarization by strongly inhibiting Kv2.1 (therefore K+ efflux). This action, together with the reduced inhibition of VDCC by open form Syn-1A, would collectively optimize Ca2+ influx during exocytosis. Direct regulation of ion channels by other exocytotic proteins is much less known, although RIM and GEFII have been implicated to interact with VDCC and KATP channels, respectively. Our recent report showing that Munc13-1 intimately interacts with GEFII and RIM to modulate insulin exocytosis (Ref. 117 ; and reviewed in Ref. 118) may suggest that this complex could also somehow modulate VDCC and KATP channels as part of the priming process for secretion. Alternatively, Munc13-1 and tomosyn may modulate VDCC and K+ channels (Kv and KATP) via their ability to alter the conformation of Syn-1A.
In diabetic rodent and human ß-cells, the reduced level of Syn-1A (32, 33, 34, 35) would be expected to affect channel functions. For example, it is expected that in such ß-cells, KATP channels have a lower sensitivity to ATP inhibition, and dialyzing Syn-1A to these cells would enhance the ATP sensitivity. Similarly, Kv2.1 channels may have higher current density and a depolarizing shift in inactivation in those diabetic ß-cells.
It would be of interest to determine whether Syn-1A-Kv interaction or Syn-1A-KATP interaction is more important in modulating insulin secretion. The use of Kir6.2 genetically engineered mice (119) and a Kv2.1 knockout (yet unavailable) may give a partial clue to the relative importance of KATP channels and Kv channels in ß-cell insulin release, but could not provide an insight into the relative importance of Syn-1A-Kv interaction and Syn-1A-KATP interaction. A feasible attempt would be to map out the "minimum-possible" binding domains of Kv2.1 and KATP channels that interact with Syn-1A. Indeed, a smaller (half) segment within C1 of Kv2.1 C terminus has already been defined, which binds strongly to Syn-1A (120). Further efforts need to be made to define subdomain(s) within SUR1-NBFs that interact with Syn-1A. These minimum-possible binding domains would desirably not prevent channel interaction with other molecules (such as RIM/GEF) but only block Syn-1A binding. It would be informative to introduce these peptide domains in pancreatic islets and examine which one would more potently impair insulin secretion.
 |
Footnotes
|
|---|
This work is supported by grants from the Canadian Institutes for Health Research (CIHR; MOP-69083), Heart and Stroke Foundation of Ontario (T-6064), and Canadian Association of Gastroenterology/Abbott Labs/CIHR (CIHR DOP 68570) (to H.Y.G.). Y.M.L. thanks China Medical University, Taiwan, and the Taiwan National Science Council for providing start-up funds (CMU95-049; CMU9182; and NSC 95-2321-B-039-001). E.P.K. is supported by a Canada Graduate Scholarship Doctoral Award from CIHR (CGD 76317), and B.N. is supported by studentships from the Ontario Graduate Studentship and the Banting and Best Diabetes Center (University of Toronto).
Disclosure Statement: The authors have nothing to disclose.
First Published Online September 18, 2007
1 Y.M.L. and E.P.K. contributed equally to this work. 
Abbreviations: GEFII, Guanyl nucleotide exchange factor II; GLP-1, glucagon-like peptide-1; KATP, ATP-sensitive K+; Kir, inward rectifier K+; Kv, voltage-gated K+; NBF, nucleotide-binding fold; PKA, protein kinase A; RIM, rab3a-interacting molecule; RRP, readily releasable pool; SNARE, soluble N-ethylmaleimide-sensitive factor attachment protein receptor; SUR, sulfonylurea receptor; Syn-1A, syntaxin-1A; VDCC, voltage-dependent Ca2+ channel; WT, wild type.
 |
References
|
|---|
- Gerber SH, Sudhof TC 2002 Molecular determinants of regulated exocytosis. Diabetes 51(Suppl 1):S3–S11
- Rizo J, Sudhof TC 2002 Snares and Munc18 in synaptic vesicle fusion. Nat Rev Neurosci 3:641–653[Medline]
- Rettig J, Neher E 2002 Emerging roles of presynaptic proteins in Ca2+-triggered exocytosis. Science 298:781–785[Abstract/Free Full Text]
- Brunger AT 2000 Structural insights into the molecular mechanism of Ca2+-dependent exocytosis. Curr Opin Neurobiol 10:293–302[CrossRef][Medline]
- Hong W 2005 SNAREs and traffic. Biochim Biophys Acta 1744:493–517[Medline]
- Wheeler M, Sheu L, Ghai M, Bouquillon A, Grondin G, Weller U, Beaudoin AR, Bennett MK, Trimble WS, Gaisano HY 1996 Characterisation of SNARE protein expression in ß-cell lines and pancreatic islets. Endocrinology 137:1340–1348[Abstract]
- Huang XH, Wheeler MB, Kang YH, Sheu L, Lukacs G, Trimble WS, Gaisano HY 1998 Truncated SNAP-25 (1-197), like botulinum neurotoxin A inhibits insulin secretion from HIT-T15 insulinoma cells. Mol Endocrinol 12:1060–1070[Abstract/Free Full Text]
- Lang J, Zhang H, Vaidyanathan VV, Sadoul K, Niemann H, Wollheim CB 1997 Transient expression of botulinum neurotoxin C1 light chain differentially inhibits calcium and glucose induced insulin secretion in clonal ß-cells. FEBS Lett 419:13–17[CrossRef][Medline]
- Dulubova I, Sugita S, Hill S, Hosaka M, Fernandez I, Sudhof TC, Rizo J 1999 A conformational switch in syntaxin during exocytosis: role of munc18. EMBO J 18:4372–4382[CrossRef][Medline]
- Yang B, Steegmaier M, Gonzalez LC, Scheller, RH 2000 nSec1 binds a closed conformation of syntaxin1A. J Cell Biol 148:247–252[Abstract/Free Full Text]
- Brose N, Rosenmund C, Rettig J 2000 Regulation of transmitter release by Unc-13 and its homologues. Curr Opin Neurobiol 10:303–311[CrossRef][Medline]
- Richmond JE, Weimer RM, Jorgensen EM 2001 An open form of syntaxin bypasses the requirement for UNC-13 in vesicle priming. Nature 412:338–341[CrossRef][Medline]
- Ashcroft FM, Proks P, Smith PA, Ammala C, Bokvist K, Rorsman P 1994 Stimulus-secretion coupling in pancreatic ß cells. J Cell Biochem 55(Suppl):54–65
- Catterall WA 2000 Structure and regulation of voltage-gated Ca2+ channels. Annu Rev Cell Dev Biol 16:521–555[CrossRef][Medline]
- Catterall WA 1999 Interactions of presynaptic Ca2+ channels and snare proteins in neurotransmitter release. Ann NY Acad Sci 868:144–159[CrossRef][Medline]
- Wiser O, Trus M, Hernandez A, Renstrom E, Barg S, Rorsman P, Atlas D 1999 The voltage sensitive Lc-type Ca2+ channel is functionally coupled to the exocytotic machinery. Proc Natl Acad Sci USA 96:248–253[Abstract/Free Full Text]
- Bezprozvanny I, Zhong P, Scheller RH, Tsien RW 2000 Molecular determinants of the functional interaction between syntaxin and N-type Ca2+ channel gating. Proc Natl Acad Sci USA 97:13943–13948[Abstract/Free Full Text]
- Yang SN, Larsson O, Branstrom R, Bertorello AM, Leibiger B, Leibiger IB, Moede T, Kohler M, Meister B, Berggren PO 1999 Syntaxin 1 interacts with the L(D) subtype of voltage-gated Ca(2+) channels in pancreatic ß cells. Proc Natl Acad Sci USA 96:10164–10169[Abstract/Free Full Text]
- Atlas D 2001 Functional and physical coupling of voltage-sensitive calcium channels with exocytotic proteins: ramifications for the secretion mechanism. J Neurochem 77:972–985[CrossRef][Medline]
- Kang Y, Huang X, Pasyk EA, Ji J, Holz GG, Wheeler MB, Tsushima RG, Gaisano HY 2002 Syntaxin-3 and syntaxin-1A inhibit L-type calcium channel activity, insulin biosynthesis and exocytosis in ß-cell lines. Diabetologia 45:231–241[CrossRef][Medline]
- Ji J, Yang SN, Huang X, Li X, Sheu L, Diamant N, Berggren PO, Gaisano HY 2002 Modulation of L-type Ca2+ channels by distinct domains within SNAP-25. Diabetes 51:1425–1436[Abstract/Free Full Text]
- Jarvis SE, Barr W, Feng ZP, Hamid J, Zamponi GW 2002 Molecular determinants of syntaxin 1 modulation of N-type calcium channels. J Biol Chem 277:44399–44407[Abstract/Free Full Text]
- Ashcroft F, Rorsman P 2004 Type 2 diabetes mellitus: not quite exciting enough? Hum Mol Genet 13(Spec No 1):R21–R31
- MacDonald PE, Wheeler MB 2003 Voltage-dependent K(+) channels in pancreatic ß cells: role, regulation and potential as therapeutic targets. Diabetologia 46:1046–1062[CrossRef][Medline]
- Fili O, Michaelevski I, Bledi Y, Chikvashvili D, Singer-Lahat D, Boshwitz H, Linial M, Lotan I 2001 Direct interaction of a brain voltage-gated K+ channel with syntaxin 1A: functional impact on channel gating. J Neurosci 21:1964–1974[Abstract/Free Full Text]
- Michaelevski I, Chikvashvili D, Tsuk S, Fili O, Lohse MJ, Singer-Lahat D, Lotan I 2002 Modulation of a brain voltage-gated K+ channel by syntaxin 1A requires the physical interaction of Gß
with the channel. J Biol Chem 277:34909–34917[Abstract/Free Full Text] - Leung YM, Kang Y, Gao X, Xia F, Xie H, Sheu L, Tsuk S, Lotan I, Tsushima RG, Gaisano HY 2003 Syntaxin 1A binds to the cytoplasmic C terminus of Kv2.1 to regulate channel gating and trafficking. J Biol Chem 278:17532–17538[Abstract/Free Full Text]
- Michaelevski I, Chikvashvili D, Tsuk S, Singer-Lahat D, Kang Y, Linial M, Gaisano HY, Fili O, Lotan I 2003 Direct interaction of target SNAREs with the Kv2.1 channel. Modal regulation of channel activation and inactivation gating. J Biol Chem 278:34320–34330[Abstract/Free Full Text]
- Pasyk E, Kang Y, Huang X, Cui N, Sheu L, Gaisano HY 2004 Syntaxin-1A binds the nucleotide-binding folds of sulphonylurea receptor 1 to regulate the KATP channel. J Biol Chem 279:4234–4240[Abstract/Free Full Text]
- Cui N, Kang Y, He Y, Leung YM, Xie H, Pasyk EA, Gao XD, Sheu L, Hansen JB, Wahl P, Tsushima RG, Gaisano HY 2004 H3 domain of syntaxin 1A inhibits KATP channels by its actions on the sulfonylurea receptor 1 nucleotide-binding folds-1 and -2. J Biol Chem 279:53259–53265[Abstract/Free Full Text]
- Leung YM, Kang Y, Xia F, Gao X, Xie H, Sheu L, Tsushima RG, Gaisano HY 2005 Open form syntaxin 1A is a more potent inhibitor than the wild type form in inhibiting Kv2.1 channel. Biochem J 387:195–202[CrossRef][Medline]
- Gaisano HY, Ostenson CG, Sheu L, Wheeler WB, Efendic S 2002 Abnormal expression of pancreatic islet exocytotic SNARE proteins in GK rats is partially restored by phlorizin and accentuated by high glucose treatment. Endocrinology 143:4218–4226[Abstract/Free Full Text]
- Ostenson CG, Gaisano HY, Sheu L, Tibell A, Bartfai T 2006 Impaired gene and protein expression of exocytotic SNARE complex proteins in pancreatic islets of type 2 diabetic patients. Diabetes 55:435–440[Abstract/Free Full Text]
- Chan CB, MacPhail RM, Sheu L, Wheeler MB, Gaisano HY 1999 ß-Cell hypertrophy in fa/fa rats is associated with basal glucose hypersensitivity and reduced SNARE protein expression. Diabetes 48:997–1005[Abstract]
- Ostenson CG, Chen J, Sheu L, Gaisano HY 2007 Effects of palmitate on insulin secretion and exocytotic proteins in pancreatic islets of diabetic Goto-Kakizaki rats. Pancreas 34:359–363[CrossRef][Medline]
- Nagamatsu S, Nakamichi Y, Yamamura C, Matsushima S, Watanabe T, Ozawa S, Furukawa H, Ishida H 1999 Decreased expression of t-SNARE, syntaxin 1, and SNAP-25 in pancreatic ß-cells is involved in impaired insulin secretion from diabetic GK rat islets: restoration of decreased t-SNARE proteins improves impaired insulin secretion. Diabetes 48:2367–2373[Abstract]
- Choe S, Kreusch A, Pfaffinger PJ 1999 Towards the three-dimensional structure of voltage-gated potassium channels. Trends Biochem Sci. 24:345–349
- Choe S 2002 Potassium channel structures. Nat Rev Neurosci 3:115–121[CrossRef][Medline]
- MacDonald PE, Ha XF, Wang J, Smukler SR, Sun AM, Gaisano HY, Salapatek AM, Backx PH, Wheeler MB 2001 Members of the Kv1 and Kv2 voltage-dependent K(+) channel families regulate insulin secretion. Mol Endocrinol 15:1423–1435[Abstract/Free Full Text]
- Yamakawa T, Saith S, Li Y, Gao X, Gaisano HY, Tsushima RG, Syntaxin 1A interacts with the KCHiP2 N–terminal binding site of Kv4.2 to modulate channel trafficking and gating. Biochemistry, in press
- Ji J, Salapatek AM, Lau H, Wang G, Gaisano HY, Diamant NE 2002 SNAP-25, a SNARE protein, inhibits two types of K channels in esophageal smooth muscle. Gastroenterology 122:994–1006[CrossRef][Medline]
- Roe MW, Worley 3rd JF, Mittal AA, Kuznetsov A, DasGupta S, Mertz RJ, Witherspoon 3rd SM, Blair N, Lancaster ME, McIntyre MS, Shehee WR, Dukes ID, Philipson LH 1996 Expression and function of pancreatic ß-cell delayed rectifier K+ channels. Role in stimulus-secretion coupling. J Biol Chem 271:32241–32246[Abstract/Free Full Text]
- Xia F, Gao X, Kwan E, Lam PP, Chan L, Sy K, Sheu L, Wheeler MB, Gaisano HY, Tsushima RG 2004 Disruption of pancreatic ß-cell lipid rafts modifies Kv2.1 channel gating and insulin exocytosis. J Biol Chem 279:24685–24691[Abstract/Free Full Text]
- MacDonald PE, Wang G, Tsuk S, Dodo C, Kang Y, Tang L, Wheeler MB, Cattral MS, Lakey JR, Salapatek AM, Lotan I, Gaisano HY 2002 Synaptosome-associated protein of 25 kilodaltons modulates Kv2.1 voltage-dependent K(+) channels in neuroendocrine islet ß-cells through an interaction with the channel N terminus. Mol Endocrinol 16:2452–2461[Abstract/Free Full Text]
- Singer-Lahat D, Sheinin A, Chikvashvili D, Tsuk S, Greitzer D, Friedrich R, Feinshreiber L, Ashery U, Benveniste M, Levitan ES, Lotan I 2007 K+ channel facilitation of exocytosis by dynamic interaction with syntaxin. J Neurosci 27:1651–1658[Abstract/Free Full Text]
- He Y, Elias C, Huang Y, Gao X, Leung Y, Kang Y, Xie H, Tsushima R, Gaisano HY, Botulinum neurotoxin/A and /E cleavage products of SNAP-25 exhibit distinct actions on pancreatic islet ß-cell Kv2.1 channel gating. Pancreas, in press
- Herrington J, Zhou YP, Bugianesi RM, Dulski PM, Feng Y, Warren VA, Smith MM, Kohler MG, Garsky VM, Sanchez M, Wagner M, Raphaelli K, Banerjee P, Ahaghotu C, Wunderler D, Priest BT, Mehl JT, Garcia ML, McManus OB, Kaczorowski GJ, Slaughter RS 2006 Blockers of the delayed-rectifier potassium current in pancreatic ß-cells enhance glucose-dependent insulin secretion. Diabetes 55:1034–1042[Abstract/Free Full Text]
- Margittai M, Widengren J, Schweinberger E, Schroder GF, Felekyan S, Haustein E, Konig M, Fasshauer D, Grubmuller H, Jahn R, Seidel CA 2003 Single-molecule fluorescence resonance energy transfer reveals a dynamic equilibrium between closed and open conformations of syntaxin 1. Proc Natl Acad Sci USA 100:15516–15521[Abstract/Free Full Text]
- Schulla V, Renstrom E, Feil R, Feil S, Franklin I, Gjinovci A, Jing XJ, Laux D, Lundquist I, Magnuson MA, Obermuller S, Olofsson CS, Salehi A, Wendt A, Klugbauer N, Wolheim CB, Rorsman P, Hofmann F 2003 Impaired insulin secretion and glucose tolerance in ß-cell selective Cav1.2 Ca2+ channel null mice. EMBO J 22:3844–3854[CrossRef][Medline]
- Yang SN, Beggren PO 2006 The role of voltage-gated calcium channels in pancreatic ß-cell physiology and pathophysiology. Endocr Rev 27:621–676[Abstract/Free Full Text]
- Ramanadham S, Turk J 1994
-Conotoxin inhibits glucose- and arachidonic acid-induced rises in intracellular [Ca2+] in rat pancreatic islet ß-cells. Cell Calcium 15:259–264[CrossRef][Medline] - Sher E, Giovannini F, Codignola A, Passafaro M, Giorgi-Rossi P, Volsen S, Craig P, Davalli A, Carrera P 2003 Voltage-operated calcium channel heterogeneity in pancreatic ß cells: physiopathological implications. J Bioenerg Biomembr 35:687–696[CrossRef][Medline]
- Taylor JT, Huang L, Keyser BM, Zhuang H, Clarkson CW, Li M 2005 Role of high-voltage-activated calcium channels in glucose-regulated ß-cell calcium homeostasis and insulin release. Am J Physiol Endocrinol Metab 289:E900–E908
- Ohta M, Nelson J, Nelson D, Meglasson MD, Erecinska M 1993 Effects of Ca++ channel blockers on energy level and stimulated insulin secretion in isolated rat islets of Langerhans. J Pharmacol Exp Ther 264:35–40[Abstract/Free Full Text]
- Sher E, Biancardi E, Pollo A, Carbone E, Li G, Wollheim CB, Clementi F 1992
-Conotoxin-sensitive, voltage-operated Ca2+ channels in insulin-secreting cells. Eur J Pharmacol 216:407–414[CrossRef][Medline] - Pal SK, Takimoto K, Aizenman E, Levitan ES 2006 Apoptotic surface delivery of K+ channels. Cell Death Differ 13:661–667[CrossRef][Medline]
- Koster JC, Permutt MA, Nichols CG 2005 Diabetes and insulin secretion: the ATP-sensitive K+ channel connection. Diabetes 54:3065–3072[Abstract/Free Full Text]
- Babenko AP, Aguilar-Bryan L, Bryan J 1998 A view of sur/KIR6.X, KATP channels. Annu Rev Physiol 60:667–687[CrossRef][Medline]
- Aguilar-Bryan L, Bryan J 1999 Molecular biology of adenosine triphosphate-sensitive potassium channels. Endocr Rev 20:101–135[Abstract/Free Full Text]
- Bryan J, Vila-Carriles WH, Zhao G, Babenko AP, Aguilar-Bryan L 2004 Toward linking structure with function in ATP-sensitive K+ channels. Diabetes 53(Suppl 3):S104–S112
- Nichols CG 2006 KATP channels as molecular sensors of cellular metabolism. Nature 440:470–476[CrossRef][Medline]
- Cerasi E, Luft R 1967 The plasma insulin response to glucose infusion in healthy subjects and in diabetes mellitus. Acta Endocrinol (Copenh) 55:278–304[Abstract/Free Full Text]
- Ohara-Imaizumi M, Fujiwara T, Nakamichi Y, Okamura T, Akimoto Y, Kawai J, Matsushima S, Kawakami H, Watanabe T, Akagawa K, Nagamatsu S 2007 Imaging analysis reveals mechanistic differences between first- and second-phase insulin exocytosis. J Cell Biol 177:695–705[Abstract/Free Full Text]
- Shyng S, Ferrigni T, Nichols CG 1997 Regulation of KATP channel activity by diazoxide and MgADP: distinct functions of the two nucleotide binding folds of the sulfonylurea receptor. J Gen Physiol 110:643–654[Abstract/Free Full Text]
- Grill V, Bjorklund A 2001 Overstimulation and ß-cell function. Diabetes 50(Suppl 1):S122–S124
- Matsuda M, Kawasaki F, Mikami Y, Takeuchi Y, Saito M, Eto M, Kaku K 2002 Rescue of ß-cell exhaustion by diazoxide after the development of diabetes mellitus in rats with streptozotocin-induced diabetes. Eur J Pharmacol 453:141–148[CrossRef][Medline]
- Guldstrand M, Grill V, Bjorklund A, Lins PE, Adamson U 2002 Improved ß cell function after short-term treatment with diazoxide in obese subjects with type 2 diabetes. Diabetes Metab 28:448–456[Medline]
- Hansen JB, Arkhammar PO, Bodvarsdottir TB, Wahl P 2004 Inhibition of insulin secretion as a new drug target in the treatment of metabolic disorders. Curr Med Chem 11:1595–1615[Medline]
- Yoshikawa H, Ma Z, Bjorklund A, Grill V 2004 Short-term intermittent exposure to diazoxide improves functional performance of ß-cells in a high-glucose environment. Am J Physiol Endocrinol Metab 287:E1202–E1208
- Ng B, Kang Y, Elias CL, He Y, Xie H, Hansen JB, Wahl P, Gaisano HY 2007 The actions of a novel potent islet ß-cell specific KATP channel opener can be modulated by syntaxin-1A acting on sulfonylurea receptor 1. Diabetes 56:2124–2134[CrossRef][Medline]
- Alemzadeh R, Fledelius C, Bodvarsdottir T, Sturis J 2004 Attenuation of hyperinsulinemia by NN414, a SUR1/Kir6.2 selective K-adenosine triphosphate channel opener, improves glucose tolerance and lipid profile in obese Zucker rats. Metabolism 53:441–447[CrossRef][Medline]
- Gutniak M, Orskov C, Holstt JJ, Ahren B, Efendic S 1992 Antidiabetogenic effects of GLP-1 in normal subjects and patients with diabetes mellitus. N Engl J Med 326:1316–1322[Abstract]
- Holz GG, Kuhtreiber WM, Habener JF 1993 Pancreatic ß cells are rendered glucose-competent by the insulinotropic hormone GLP-1. Nature 3761:362–365
- MacDonald PE, Salapatek AM, Wheeler MB 2002 Glucagon-like peptide-1 receptor activation antagonizes voltage-dependent repolarizing K(+) currents in ß-cells: a possible glucose-dependent insulinotropic mechanism. Diabetes 51(Suppl 3):S443–S447
- MacDonald PE, Wang X, Xia F, El-kholy W, Targonsky ED, Tsushima RG, Wheeler MB 2003 Antagonism of rat ß-cell voltage-dependent K+ currents by exendin 4 requires dual activation of the cAMP/protein kinase A and phosphatidylinositol 3-kinase signaling pathways. J Biol Chem 278:52446–52453[Abstract/Free Full Text]
- Schoch S, Castillo PE, Jo T, Mjihergee K, Geppert M, Wang Y, Schmitz F, Malenka RC, Sudhof TC 2002 RIM1 forms a protein scaffold for regulating neurotransmitter release at the active zone. Nature 415:321–326[CrossRef][Medline]
- Castillo PE, Schoch S, Schmitz F, Sudhof TC, Malenka RC 2002 RIM1 is required for presynaptic long-term potentiation. Nature 415:327–330[CrossRef][Medline]
- Ozaki N, Shibasaki T, Kashima Y, Miki T, Takahashi K, Ueno H, Sunaga Y, Yano H, Matsuura Y, Iwanaga T, Takai Y, Seino S 2000 cAMP-GEFII is a direct target of cAMP in regulated exocytosis. Nat Cell Biol 2:805–811[CrossRef][Medline]
- Kashima Y, Miki T, Shibasaki T, Ozaki N, Miyazaki M, Yano H, Seino S 2001 Critical role of cAMP-GEFII-Rim2 complex in incretin-potentiated insulin secretion. J Biol Chem 276:46046–46053[Abstract/Free Full Text]
- Shibasaki T, Sunaga Y, Fujimoto K, Kashima Y, Seino S 2004 Interaction of ATP sensor, cAMP sensor, Ca2+ sensor, and voltage-dependent calcium channel in insulin granule exocytosis. J Biol Chem 279:7956–7961[Abstract/Free Full Text]
- Lonart G, Schoch S, Kaeser PS, Larkin CJ, Sudhof TC, Linden DJ 2003 Phosphorylation of RIM1
by PKA triggers presynaptic long-term potentiation at cerebellar parallel fiber synapses. Cell 115:49–60[CrossRef][Medline] - Sun L, Bittner MA, Holz RW 2001 Rab3a binding and secretion-enhancing domains in Rim1 are separate and unique. Studies in adrenal chromaffin cells. J Biol Chem 276:1291–12917[Abstract/Free Full Text]
- Gonzales Jr L, Scheller RH 1999 Regulation of membrane trafficking: structural insights from a Rab/Effector complex. Cell 96:755–758[CrossRef][Medline]
- Wang Y, Okamoto M, Schmiz F, Hofman K, Sudhof TC 1997 RIM is a putative Rab3A-effector regulating synaptic vesicle fusion. Nature 388:593–598[CrossRef][Medline]
- Betz A, Thakur P, Junge HJ, Ashery U, Rhee JS, Scheuss V, Rosenmund C, Rettig J, Brose N 2001 Functional interaction of the active zone proteins Munc13-1 and RIM1 in synaptic vesicle priming. Neuron 30:183–196[CrossRef][Medline]
- Dulubova I, Lou X, Lu J, Huryeva I, Alam A, Schneggenburger R, Sudhof TC, Rizo J 2005 A Munc13/RIM/Rab3 tripartite complex: from priming to plasticity? EMBO J 24:2839–2850[CrossRef][Medline]
- Kang G, Joseph JW, Chepurny OG, Monaco M, Wheeler MB, Bos JL, Schwede F, Genieser HG, Holz GG 2003 Epac-selective cAMP analog 8-pCPT-2'-O-Me-cAMP as a stimulus for Ca2+-induced Ca2+ release and exocytosis in pancreatic ß-cells. J Biol Chem 278:8279–8285[Abstract/Free Full Text]
- Holz GG 2004 Epac: a new cAMP-binding protein in support of glucagon-like peptide-1 receptor-mediated signal transduction in the pancreatic ß-cell. Diabetes 53:5–13[Abstract/Free Full Text]
- Fujimoto K, Shibasaki T, Yokoi N, Kashima Y, Matsumoto M, Sasaki T, Tajima N, Iwanaga T, Seino S 2002 Piccolo, a Ca2+ sensor in pancreatic ß-cells. Involvement of cAMP-GEFII.Rim2.Piccolo complex in cAMP-dependent exocytosis. J Biol Chem 277:50497–50502[Abstract/Free Full Text]
- Coppola T, Magnin-Luth S, Perret-Menoud V, Gattesco S, Schiavo G, Reggazi R 2001 Direct interactions of the Rab3 effector RIM with Ca2+ channels, SNAP-25 and synaptotagmin. J Biol Chem 276:32756–32762[Abstract/Free Full Text]
- Khanna R, Li Q, Sun L, Collins TJ, Stanley EF 2006 N type Ca2+ channels and RIM scaffold protein covary at the presynaptic transmitter release face but are components of independent protein complexes. Neuroscience 140:1201–1208[CrossRef][Medline]
- Liu G, Jacobo SM, Hilliard N, Hockerman GH 2006 Differential modulation of Cav1.2 and Cav1.3-mediated glucose-stimulated insulin secretion by cAMP in INS-1 cells: distinct roles for exchange protein directly activated by cAMP 2 (Epac2) and protein kinase A. J Pharmacol Exp Ther 318:152–160[Abstract/Free Full Text]
- Kang G, Chepurny OG, Malester B, Rindler MJ, Rehmann H, Bos JL, Schwede F, Coetzee WA, Holz GG 2006 cAMP sensor Epac as a determinant of ATP-sensitive potassium channel activity in human pancreatic ß cells and rat INS-1 cells. J Physiol 573:595–609[Abstract/Free Full Text]
- Betz A, Ashery U, Rickmann M, Augustin I, Neher E, Sudhof TC, Rettig J, Brose N 1998 Munc13-1 is a presynaptic phorbol ester receptor that enhances neurotransmitter release. Neuron 21:123–136[CrossRef][Medline]
- Brose N, Hofmann K, Hata Y, Sudhof TC 1995 Mammalian homologues of Caenorhabditis elegans unc-13 gene define novel family of C2-domain proteins. J Biol Chem 270:25273–25280[Abstract/Free Full Text]
- Ashery U, Varoqueaux F, Voets T, Betz A, Thakur P, Koch H, Neher E, Brose N, Rettig J 2000 Munc13-1 acts as a priming factor for large dense-core vesicles in bovine chromaffin cells. EMBO J 19:3586–3596[CrossRef][Medline]
- Sheu L, Pasyk EA, Ji J, Huang X, Gao X, Varoqueaux F, Brose N, Gaisano HY 2003 Regulation of insulin exocytosis by Munc13-1. J Biol Chem 278:27556–27563[Abstract/Free Full Text]
- Aravamudan B, Fergestad T, Davis WS, Rodesch CK, Broadie K 1999 Drosophila UNC-13 is essential for synaptic transmission. Nat Neurosci 2:965–971[CrossRef][Medline]
- Augustin I, Rosenmund C, Sudhof TC, Brose N 1999 Munc13-1 is essential for fusion competence of glutamatergic synaptic vesicles. Nature 400:457–461[CrossRef][Medline]
- Richmond JE, Davis WS, Jorgensen EM 1999 UNC-13 is required for synaptic vesicle fusion in C. elegans. Nat Neurosci 2:959–964[CrossRef][Medline]
- Kwan EP, Xie L, Sheu L, Nolan CJ, Prentki M, Betz A, Brose N, Gaisano HY 2006 Munc13-1 deficiency reduces insulin secretion and causes abnormal glucose tolerance. Diabetes 55:1421–1429[Abstract/Free Full Text]
- Kang L, He Z, Xu P, Fan J, Betz A, Brose N, Xu T 2006 Munc13-1 is required for the sustained release of insulin from pancreatic ß cells. Cell Metab 3:463–468[CrossRef][Medline]
- Betz A, Okamoto M, Benseler F, Brose N 1997 Direct interaction of the rat unc-13 homologue Munc13-1 with the N terminus of syntaxin. J Biol Chem 272:2520–2526[Abstract/Free Full Text]
- Madison JM, Nurrish S, Kaplan JM 2005 UNC-13 interaction with syntaxin is required for synaptic transmission. Curr Biol 15:2236–2242[CrossRef][Medline]
- Stevens DR, Wu ZX, Matti U, Junge HJ, Schirra C, Becherer U, Wojcik SM, Brose N, Rettig J 2005 Identification of the minimal protein domain required for priming activity of Munc13-1. Curr Biol 15:2243–2248[CrossRef][Medline]
- Straub SG, Sharp GW 2002 Glucose-stimulated signaling pathways in biphasic insulin secretion. Diabetes Metab Res Rev 18:451–463[CrossRef][Medline]
- Drucker DJ 2006 The biology of incretin hormones. Cell Metab 3:153–165[CrossRef][Medline]
- Ammala C, Ashcroft FM, Rorsman P 1993 Calcium-independent potentiation of insulin release by cyclic AMP in single ß-cells. Nature 363:356–358[CrossRef][Medline]
- Andrews-Zwilling YS, Kawabe H, Reim K, Varoqueaux F, Brose N 2006 Binding to RAB3a-interacting-molecule rim regulates the presynaptic recruitment of MUNC13-1 and ubMUNC13-2. J Biol Chem 281:19720–19731[Abstract/Free Full Text]
- Weimer RM, Gracheva EO, Meyrignac O, Miller KG, Richmond JE, Bessereau JL 2006 UNC-13 and UNC-10/rim localize synaptic vesicles to specific membrane domains. J Neurosci 26:8040–8047[Abstract/Free Full Text]
- Fujita Y, Shirataki H, Sakisaka T, Asakura T, Ohya T, Kotani H, Yokoyama S, Nishioka H, Matsuura Y, Mizoguchi A, Scheller RH, Takai Y 1998 Tomosyn: a syntaxin-1-binding protein that forms a novel complex in the neurotransmitter release process. Neuron 20:905–915[CrossRef][Medline]
- McEwen JM, Madison JM, Dybbs M, Kaplan JM 2006 Antagonistic regulation of synaptic vesicle priming by Tomosyn and UNC-13. Neuron 51:303–315[CrossRef][Medline]
- Yizhar O, Matti U, Melamed R, Hagalili Y, Bruns D, Rettig J, Ashery U 2004 Tomosyn inhibits priming of large dense-core vesicles in a calcium-dependent manner. Proc Natl Acad Sci USA 101:2578–2583[Abstract/Free Full Text]
- Zhang W, Lilja L, Mandic SA, Gromada J, Smidt K, Janson J, Takai Y, Bark C, Berggren PO, Meister B 2006 Tomosyn is expressed in ß-cells and negatively regulates insulin exocytosis. Diabetes 55:574–581[Abstract/Free Full Text]
- Baba T, Sakisaka T, Mochida S, Takai Y 2005 PKA-catalyzed phosphorylation of tomosyn and its implication in Ca2+-dependent exocytosis of neurotransmitter. J Cell Biol 170:1113–1125[Abstract/Free Full Text]
- Cheviet S, Bezzi P, Ivarsson R, Renström E, Viertl D, Kasas S, Catsicas S, Regazzi R 2006 Tomosyn-1 is involved in a post-docking event required for pancreatic ß-cell exocytosis. J Cell Sci 119:2912–2920[Abstract/Free Full Text]
- Kwan EP, Xie L, He Y, Sheu L, Ohtsuka T, Gaisano HY, Interaction between Munc13-1 and RIM is critical for glucagon-like peptide-1-mediated rescue of exocytotic defects in Munc13-1-deficient pancreatic ß-cells. Diabetes, in press
- Kwan EP, Gaisano HY, New insights into the molecular mechanisms of priming of insulin exocytosis. Diabetes Obes Metab, in press
- Seino S, Iwanaga T, Nagashima K, Miki T 2000 Diverse roles of K(ATP) channels learned from Kir6.2 genetically engineered mice. Diabetes 49:311–318[Abstract]
- Tsuk S, Michaelevski I, Bentley GN, Joho RH, Chikvashvili D, Lotan I 2005 Kv2.1 channel activation and inactivation is influenced by physical interactions of both syntaxin 1A and the syntaxin 1A/soluble N-ethylmaleimide-sensitive factor-25 (t-SNARE) complex with the C terminus of the channel. Mol Pharmacol 67:480–488[Abstract/Free Full Text]
This article has been cited by other articles:

|
 |

|
 |
 
A. Honsbein, S. Sokolovski, C. Grefen, P. Campanoni, R. Pratelli, M. Paneque, Z. Chen, I. Johansson, and M. R. Blatt
A Tripartite SNARE-K+ Channel Complex Mediates in Channel-Dependent K+ Nutrition in Arabidopsis
PLANT CELL,
September 1, 2009;
21(9):
2859 - 2877.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. M. P. Jacobo, M. L. Guerra, R. E. Jarrard, J. A. Przybyla, G. Liu, V. J. Watts, and G. H. Hockerman
The Intracellular II-III Loops of Cav1.2 and Cav1.3 Uncouple L-Type Voltage-Gated Ca2+ Channels from Glucagon-Like Peptide-1 Potentiation of Insulin Secretion in INS-1 Cells via Displacement from Lipid Rafts
J. Pharmacol. Exp. Ther.,
July 1, 2009;
330(1):
283 - 293.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. Zhang, R. Luo, H. Wu, S. Wei, W. Han, and G. Li
Role of Type I{alpha} Phosphatidylinositol-4-Phosphate 5-Kinase in Insulin Secretion, Glucose Metabolism, and Membrane Potential in INS-1 {beta}-Cells
Endocrinology,
May 1, 2009;
150(5):
2127 - 2135.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
B. Ng, Y. Kang, H. Xie, H. Sun, and H. Y. Gaisano
Syntaxin-1A inhibition of P-1075, cromakalim, and diazoxide actions on mouse cardiac ATP-sensitive potassium channel
Cardiovasc Res,
December 1, 2008;
80(3):
365 - 374.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Prentki and S. R. M. Madiraju
Glycerolipid Metabolism and Signaling in Health and Disease
Endocr. Rev.,
October 1, 2008;
29(6):
647 - 676.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. L. R. Williams, G. K. Fyfe, C. P. Sibley, P. N. Baker, and S. L. Greenwood
K+ channel inhibition modulates the biochemical and morphological differentiation of human placental cytotrophoblast cells in vitro
Am J Physiol Regulatory Integrative Comp Physiol,
October 1, 2008;
295(4):
R1204 - R1213.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. C. Bassham and M. R. Blatt
SNAREs: Cogs and Coordinators in Signaling and Development
Plant Physiology,
August 1, 2008;
147(4):
1504 - 1515.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. Eliasson, F. Abdulkader, M. Braun, J. Galvanovskis, M. B. Hoppa, and P. Rorsman
Novel aspects of the molecular mechanisms controlling insulin secretion
J. Physiol.,
July 15, 2008;
586(14):
3313 - 3324.
[Abstract]
[Full Text]
[PDF]
|
 |
|